This High-Yield ETF Has Increased Payouts 13 Years Straight -- and It's Still Undervalued

Schwab U.S. Dividend Equity ETF (SCHD) uses a rules-based screen (minimum 10 years of dividend payments, above-average yield, and filters on ROE, cash-flow-to-debt, dividend yield and 5-year dividend growth) to select 100 market-cap-weighted stocks; roughly 85% of holdings have at least 10 years of dividend growth. The fund has increased its annual payout every year since inception (2011 payout $0.0406; 2024 $0.9944), has paid $0.7694 through Q3 2025 (needs ≥$0.23 Q4 to extend to 14 years), and offers a 3.8% yield, 16.7 P/E versus S&P 500's 25, and a 0.06% expense ratio—positioning it as a lower-valuation, income-oriented, defensive ETF concentrated in energy, consumer staples, healthcare, industrials and financials.

Analysis

Market structure: Income-focused winners include dividend ETFs (SCHD) and their large-cap, cash-generative components (KO, ABBV, AMGN, CSCO). Value/dividend sectors (energy 19%, staples 18.5%, healthcare 16%) gain relative share vs growth; P/E gap (SCHD 16.7 vs S&P 25) implies ~30–40% downside protection vs cyclical drawdowns over 6–12 months if growth multiple compressions recur.

Risk assessment: Key tail risks are a sharp oil-price collapse (hurting SCHD's 19% energy weight), adverse drug-pricing regulation hitting ABBV/AMGN, or a rapid Fed pivot causing yield compression that hurts dividend yield premium. Immediate (days): Q4 dividend announcement (late Dec) is a binary; short-term (weeks–months): earnings and oil/CPI; long-term (quarters–years): secular dividend growth may stall if recessions reduce free cash flow.

Trade implications: Favor a conservative long in SCHD (income + lower P/E) and selective longs in KO/ABBV; hedge sector concentration by selling short high-multiple growth exposure (XLK or QQQ) equal to 30–50% dollar-weight of the long. Use covered-call overlays to enhance yield or buy 3–6 month puts to limit 8–12% downside; rotate into industrials/financials on rate-steepening signals.

Contrarian angles: Consensus underprices the rebalancing risk inside SCHD (energy overweight can flip monthly returns) and overprices dividend-stability — a Q4 payout < $0.23 would materially break the growth streak and trigger outflows. Historically, value rotations (2000, 2016) reversed; if rates fall 50–100bps next 6–12 months, dividend ETF outperformance could be reduced by 200–400bp relative to growth.

Key Decisions for Investors

• Establish a 2–3% core long position in SCHD within 1–2 weeks to capture 3.8% yield and defensive P/E; set tactical stop-loss at 10% drawdown or reduce to 1% if SCHD Q4 dividend announced < $0.23 (due late Dec).
• Initiate long positions in KO and ABBV (1% each of portfolio) on any 5–10% pullback from current levels; target 12–18 month holding period, take profits at +20%, tighten stops to -8% after earnings that miss consensus.
• Enter a relative-value pair: long SCHD (3% weight) vs short XLK or QQQ (1.5% weight) to exploit P/E gap; rebalance monthly and widen short if tech rallies >8% in 30 days.
• Implement option overlays: sell 1–3 month covered calls 3–5% OTM on SCHD to boost yield by ~100–200bp annually, and buy 3–6 month puts 5–7% OTM as tail insurance if portfolio exposure to dividend equities >5%.
• Monitor three catalysts over next 60 days — SCHD Q4 dividend level, WTI crude ±10% moves, and any US drug-pricing legislation — and reduce dividend-equity exposure by 50% within 5 trading days if two of three trigger adverse outcomes.